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Impact of Clopidogrel in Patients With Acute Coronary
Syndromes Requiring Coronary Artery Bypass Surgery
A Multicenter Analysis
Jeffrey S. Berger, MD, MS,* Carla B. Frye, PHARMD,† Qing Harshaw, MD, PHD,†
Fred H. Edwards, MD,‡ Steven R. Steinhubl, MD,§ Richard C. Becker, MD*
Durham, North Carolina; Oak Brook, Illinois; Jacksonville, Florida; and Lexington, Kentucky
Objectives The purpose of our multicenter study was to examine the impact of pre-operative administration of clopidogrel
on reoperation rates, incidence of life-threatening bleeding, inpatient length of stay, and other bleeding-related
outcomes in acute coronary syndrome (ACS) patients requiring cardiopulmonary bypass (coronary artery bypass
graft surgery [CABG]) in a broad cross section of U.S. hospitals.
Background There is relative uncertainty about the relationship between clopidogrel and CABG-associated outcomes in the
setting of ACS.
Methods A retrospective cohort analysis was performed of randomly selected ACS patients requiring CABG in 14 hospitals
across the U.S. Patients exposed to clopidogrel were compared with those not exposed to clopidogrel within 5
days prior to surgery.
Results Of the 596 patients enrolled in the study, 298 had been exposed to clopidogrel within 5 days (Group A). Patients
in Group A were more than 3-fold more likely to require reoperation for assessment of bleeding than patients
not exposed to clopidogrel (6.4% vs. 1.7% Group B, p  0.004). Major bleeding occurred in 35% of Group A pa-
tients versus 26% of Group B patients (p  0.049). Length of stay was greater in Group A compared with Group
B (9.7  6.0 days vs. 8.6  4.7 days, unadjusted p  0.016). After logistic regression analysis, clopidogrel expo-
sure within 5 days of CABG was the strongest predictor of reoperation (odds ratio [OR]: 4.60, 95% confidence
interval [CI]: 1.45 to 14.55) and major bleeding (OR: 1.824, 95% CI: 1.106 to 3.008).
Conclusions After ACS, patients who undergo CABG within 5 days of receiving clopidogrel are at increased risk for reopera-
tion, major bleeding, and increased length of stay. These risks must be balanced by the clinical benefits of clopi-
dogrel use demonstrated in randomized clinical trials. (J Am Coll Cardiol 2008;52:1693–701) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.08.031a
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pandomized clinical trials have demonstrated the superior-
ty of clopidogrel versus placebo on a background of aspirin
herapy in the setting of acute coronary syndrome (ACS)
1–3). Although clopidogrel causes an increase in major
leeding, its main effect is in reducing cardiovascular mor-
idity and mortality in this high-risk group of patients (4).
ccordingly, the most recent ACS guidelines make early
lopidogrel treatment a class I recommendation with grade
evidence (5,6). However, one must exercise caution
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esign or conduct of the structured review, nor in the collection, management,
nalyses, or interpretation of the data. AstraZeneca, LP, was given the opportunity to
eview and comment on the final draft manuscript. The authors had full editorial
ndependence and full responsibility for the final version of the manuscript. Drs. Frye administering clopidogrel to patients undergoing surgical
evascularization. Current guidelines support the discontin-
ation of clopidogrel 5 to 7 days before elective coronary
rtery bypass graft surgery (CABG), whereas more urgent
urgery, if necessary, may be performed by experienced
urgeons if the incremental bleeding risk is considered
cceptable (5).
Accumulating data suggest that between 10% and 16% of
atients admitted with ACS undergo surgical revasculariza-
nd Harshaw are employees of EPI-Q, Inc., an independent health and economics
esearch group contracted by AstraZeneca, LP. Drs. Berger, Becker, Steinhubl, and
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ization (7–9). Although not all
(10), several retrospective studies
have reported a relationship be-
tween use of clopidogrel and the
risk of perioperative bleeding and
blood product transfusion (9,11–
14). The existing data have sev-
eral important limitations; many
studies were undertaken at single
centers (10–12,14), used a cut-
off of 5 days (9), (thus not per-
mitting an evaluation of time
from drug cessation and bleed-
ng), or did not report a full range of potential confounders
laboratory values, coagulation markers, and operative find-
ngs) or clinically relevant adverse events such as surgical
e-exploration (9). Furthermore, many published studies
ere not performed in the ACS setting (10,12–14) or
ncluded patients several weeks, on average, after their
resenting ACS event (13), a time when the bleeding risk is
ubstantially lower. As a result, the American College of
ardiology/American Heart Association (ACC/AHA)
uideline Committee for the Management of Patients
ith Unstable Angina/Non–ST-Elevation Myocardial In-
arction believes that more data on the overall relative
enefits versus risks of clopidogrel and bypass surgery are
equired to further direct patient care (5).
To better characterize the relationship between clopi-
ogrel administration and bypass surgery in the setting of
CS, we prospectively developed a multicenter protocol to
ollect patient-level hospitalization data. Study cohorts at
ndividual sites were randomly selected to reduce potential
onfounders of variability in surgical practice and standards
f care in each hospital setting. Using this study design, we
ere able to investigate the association between the prox-
mity of clopidogrel exposure and CABG-related adverse
vents, including reoperation and bleeding-related outcomes.
ethods
his study was a protocol-driven, retrospective cohort
nalysis of randomly selected patients with an admitting
iagnosis of ACS undergoing CABG during their index
ospitalization at 14 hospitals across the U.S. Stand-alone
ardiac specialty hospitals were not included. A coinvestigator
nd study coordinator were recruited at each participating
ospital site. Each site’s coinvestigator was responsible for
ubmitting the protocol to the institution’s Investigational
eview Board for evaluation and approval.
etting. The study population included patients from hos-
itals that performed at least 350 CABG procedures annu-
lly. Hospitals were selected from a broad geographic
istribution, with no more than 4 hospitals from any of 4
eographic regions of the U.S. (Northeast, Midwest, South,
Abbreviations
and Acronyms
ACC/AHA  American
College of Cardiology/
American Heart Association
ACS  acute coronary
syndrome
CABG  coronary artery
bypass graft surgery
CI  confidence interval
LOS  length of stay
OR  odds rationd West including Alaska and Hawaii). The study insti- Cutions included both teaching and nonteaching hospitals
nd those performing both on-pump and off-pump proce-
ures. To qualify for study participation, sites were required
o demonstrate that their standard of care for patients with
n admitting diagnosis of ACS permitted those requiring
ABG, upon the discretion of the treating cardiologist and
ardiothoracic surgeon, to proceed to surgery whether or not
lopidogrel had been administered. Site recruitment began
n November 2006 and concluded in August 2007. Case
ecords of patients treated between January 2004 and
ecember 2006 were included in the study. (The partici-
ating hospitals and health care systems and coinvestigators
re listed in the Online Appendix.)
Each study coordinator was trained in the study proce-
ures and case report form by 1 of the investigators and
rovided with a randomization table for selection of cases.
ites randomly selected up to 50 cases (25 in each of the 2
omparison groups using a randomization table) meeting
nclusion/exclusion to achieve a pre-specified 1:1 ratio of
atients either exposed (Group A) or not exposed (Group
) to clopidogrel within 5 days of surgery. Group B
ncluded patients who were clopidogrel naïve or those who
ad received a dose 5 days before the time of CABG.
nclusion in either group was determined by subtracting the
ate and time of the last dose of clopidogrel from the date
nd time of the initial sternotomy incision.
Data from 14 participating sites on a total of 677
atients were collected for the study. In sites that had
ewer than 25 cases in either cohort for the study period,
ases and controls were randomly selected to provide an
qual number in each cohort to reduce confounding site-
pecific characteristics that could bias or skew the results in
he overall group. Case records from 596 patients were used
n this analysis (Fig. 1).
nrollment criteria. Patients were included if they met
ach of the following criteria: 30 years of age, presented
ith ACS, underwent CABG during the index hospital-
zation, and remained at 1 hospital for management
unless complete records were available from a referring
ospital). Patients were excluded if they met any of the
ollowing criteria: end-stage renal disease, other open-
eart procedures (e.g., valvular replacement or repair,
entricular septal defect repair) with CABG, bleeding
isorder identified pre-operatively (e.g., Von Willebrand
isease, hemophilia), lost to follow-up within 30 days
fter CABG surgery, death unrelated to cardiac condition
r surgery, surgery not performed within 7 days of the
ndex hospitalization or angiography for ACS, presumed
ardiac rupture (post-infarction), and chronic use of
orticosteroids.
nd points. There were 3 coprimary end points in this
nalysis: reoperation, major bleeding, and length of hospital
tay. Major bleeding was defined as a 5 g/dl drop in
emoglobin, intracranial bleed, fatal bleed, or cardiac tam-
onade. In addition to this definition, we also evaluated the
URE (Clopidogrel in Unstable Angina to Prevent Recur-
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November 18, 2008:1693–701 CABG in ACS With Clopidogrelent Events) study (3) definition of major bleeding (sub-
tantially disabling bleeding, intraocular bleeding leading to
he loss of vision, or bleeding necessitating the transfusion
f at least 4 units of blood), and the TIMI (Thrombolysis In
yocardial Infarction) study (15) definition of life-
hreatening major bleeding (intracranial bleeding, hemor-
hagic death, cardiac tamponade, or any clinically apparent
leeding associated with a decrease in hemoglobin of 5
/dl or a 15% reduction in hematocrit-adjusted for red
lood cell transfusions).
ample size. A sample size calculation performed before
tudy initiation indicated that inclusion of 310 patients in
ach group would allow 80% power to detect a probability of
.565 that length of stay (LOS) was shorter in Group B
han Group A using a Wilcoxon (Mann-Whitney) rank
um test, with a 0.050 2-sided significance level. The
stimate of probability of differences was calculated assum-
ng a median LOS of 9 days in Group A and a median LOS
f 7 days in Group B.
tatistical analysis. The chi-square test was used for cat-
gorical variables. For continuous variables, we used either
he Student t test or the Mann-Whitney U test depending
n whether the data were normally distributed. The rela-
ionships between different treatment variables were as-
essed before and during regression analysis for multicolin-
arity. The correlation was assessed by using the Pearson
orrelation coefficient. If the correlation coefficient between
variables was0.7 and statistically significant, then only 1
Figure 1 Study Populationf the variables was used in regression model. The primary dutcomes of the study were assessed by univariate analysis,
ollowed by logistic regression analysis, to identify indepen-
ent predictive variables from the categorical and continuous
ariables. Potential confounders were entered into models if
hey were clinically relevant or showed statistical significance at
 0.10 during the univariate analysis between the 2 groups.
e also used the propensity scores risk adjustment method to
djust baseline characteristics and/or clinical factors that could
mpact the decision to give patients clopidogrel.
A p value of 0.05 was considered to declare statistical
ignificance. All analyses were performed using SPSS ver-
ion 15.0 (SPSS, Inc., Chicago, Illinois), and STATA
STATA Corp., College Station, Texas).
esults
ourteen sites across the U.S. were included in this study
Online Appendix). All patients underwent CABG within
days of their index hospitalization or angiography for
CS. Of the 596 patients enrolled in the study, 298 were in
roup A and 298 in Group B. In Group A, the mean time
etween last clopidogrel exposure and CABG surgery was
6  48.11 h, 95 had received a loading dose (most
ommonly 300 mg), and 230 received a maintenance dose
most commonly 75 mg).
Overall, mean age was 64 years, 68% were male, and 89%
ere white. Table 1 provides a summary of baseline char-
cteristics. Patients in Group A had a greater prevalence of
rior cerebrovascular accident, myocardial infarction, and
ercutaneous coronary intervention. The classification of
CS on admission was similar between groups (Table 2).
he number of vessels grafted and use of the left internal
ammary artery as a bypass conduit were less in the
lopidogrel-exposed group. Surgery was postponed for 46
atients in Group A compared with 32 patients in Group B
p  0.001). As expected, antifibrinolytic drugs were used
ore frequently in the operating room for Group A patients
han for Group B patients (66% vs. 56%, respectively, p 
.0009).
The overall incidence of reoperation, excessive or major
leeding, and LOS was influenced significantly by pre-
perative clopidogrel exposure in the univariate analysis
Table 3). Length of stay was on average 1 day longer in
roup A than in Group B. There were 24 (4.0%) reopera-
ions in the combined cohort. Patients in Group A were
ore likely to require reoperation than were patients in
roup B (6.4% vs. 1.7%, p  0.004). As expected, the
ajority of reoperations were performed for the manage-
ent of bleeding complications. After multivariable adjust-
ent, clopidogrel exposure within 5 days was the strongest
redictor of reoperation (odds ratio [OR]: 4.60, 95% con-
dence interval [CI]: 1.45 to 14.55, p  0.01) (Table 4).
ajor bleeding occurred in 124 (20.8%) patients: 35% in
roup A versus 26% in Group B (p  0.049). This finding
as numerically consistent across each of the major bleeding
efinitions evaluated (3,15). After logistic regression analy-
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CABG in ACS With Clopidogrel November 18, 2008:1693–701is for the combined end point of major bleeding or
eoperation, clopidogrel exposure within 5 days was associ-
ted with a significantly increased risk (OR: 1.55, 95% CI:
.00 to 2.41, p 0.048, data not shown). We also ran these
nalyses using the propensity score method to control for
onfounding and demonstrated an increased risk for reop-
ration (OR: 9.80, 95% CI: 2.18 to 43.95, p  0.01), major
leeding (OR: 1.82, 95% CI: 1.11 to 3.01, p  0.02), and
ncreased LOS (OR: 1.47, 95% CI: 1.00 to 2.165, p 0.05)
ith clopidogrel exposure within 5 days. Figure 2 illustrates
he incidence of reoperation or major bleeding according to
he proximity of clopidogrel exposure, and its subsequent
essation, before surgery.
There was no difference in mean hematocrit on admis-
ion, or during pre-operative or intraoperative testing be-
ween the groups. However, in the immediate post-
perative period, and on post-operative days 1 and 2, mean
ematocrit was lower in Group A than in Group B (p 
.05, for all). No difference was detected between groups in
outine coagulation measurements of international normal-
zed ratio, prothrombin time, or partial thromboplastin time
t any time point. There was a 2-fold increase in blood
roduct transfusions among patients in Group A compared
ith Group B. Table 5 describes the relationship between
lopidogrel exposure, timing of transfusions, and chest tube
utput. Patients exposed to clopidogrel were more likely to
eceive transfusions both in the intraoperative and post-
perative periods. In addition, they were also more likely to
ave received a platelet transfusion intraoperatively. In the
ost-operative period, transfusion of platelets, packed red
lood cells, fresh frozen plasma, and cryoprecipitate were all
Baseline Characteristics
Table 1 Baseline Characteristics
Group
Baseline demographics
Age, yrs (SD) 64.5
BMI, kg/m2 (SD) 29.1
Male, n (%) 207
Caucasian, n (%) 264
Clinical history
Diabetes mellitus, n (%) 103
Admission creatinine clearance, n (%)
30 ml/min 57
30–60 ml/min 104
60 ml/min 128
Hypertension, n (%) 230
Congestive heart failure, n (%) 28
Previous CABG, n (%) 17
Previous MI, n (%) 85
Previous PCI, n (%) 98
COPD, n (%) 38
CVA, n (%) 35
Current tobacco smoker, n (%) 77
Alcohol abuse, n (%) 22
BMI  body mass index; BSA  body surface area; CABG  coronary
CVA  cerebrovascular accident; MI  myocardial infarction; PCI  psed more frequently in Group A. The increase in chest aube output for Group A compared with Group B was
reatest in the first 6 h (Table 5). Multivariate analysis
onfirmed that group A patients received more blood
ransfusions and had more chest tube output when control-
ing all other factors (data not shown).
There were 5 deaths in the study population, 4 in Group
and 1 in the Group B. No significant difference was
etected for the composite of death, reinfarction, or stroke.
roup A patients were more likely to require inotropes and
o have cardiac tamponade than were Group B patients. No
ignificant difference was observed between groups for
ospital readmission within 30 days of discharge.
iscussion
n this large, prospectively designed, retrospective cohort
tudy to evaluate the relationship between clopidogrel ex-
osure and CABG-related outcomes among patients with
CS, we found a significantly increased risk of reoperation,
ajor bleeding, and LOS among those who received clopi-
ogrel within 5 days of their surgery. Our data showed a
lear dependency between time of clopidogrel cessation and
ABG-related bleeding.
In addition to “hard” clinical end points such as major
leeding and reoperation, we also evaluated the reason for
eoperation, as well as laboratory parameters before, during,
nd after surgery. A major strength of our study is its
epresentation of practice in multiple centers across the U.S.
nd inclusion of patients treated in rural and urban, teaching
nd nonteaching, and not-for-profit and for-profit hospi-
als. As a result, the data are likely to be more generalizable
298) Group B (n  298) p Value
.24) 64.0 (10.88) 0.625
3) 30.2 (5.86) 0.026
) 200 (67.1) 0.538
) 259 (88.1) 0.591
) 112 (37.6) 0.443
) 50 (17.1) 0.408
) 128 (43.7) 0.058
) 115 (39.2) 0.218
) 234 (78.5) 0.693
26 (8.7) 0.775
13 (4.4) 0.454
) 57 (19.1) 0.007
) 46 (15.4) 0.001
) 35 (11.7) 0.708
) 20 (6.7) 0.034
) 84 (28.2) 0.518
8 (2.7) 0.009
ypass graft surgery; COPD  chronic obstructive pulmonary disease;
eous coronary intervention.A (n 
(11
(6.1
(69.5
(89.5
(34.6
(19.7
(36.0
(44.3
(77.2
(9.4)
(5.7)
(28.5
(32.9
(12.8
(11.7
(25.8
(7.4)nd not dominated by individual surgeons, processes of care,
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Table 2 Clinical Presentation and Hospital Course
Group A (n  298) Group B (n  298) p Value*
ACS admission diagnosis, n (%)†
Unstable angina 203 (68.1) 187 (62.8) 0.168
NSTE ACS 93 (31.2) 85 (28.5) 0.474
STE ACS 56 (18.8) 45 (15.1) 0.230
PCI, n (%) (n  33) (n  11)
PCI initially successful then failed 12 (36.4) 4 (36.4) 1.000
PCI initially failed 21 (63.6) 7 (63.6) 1.000
Angiogram vessel anatomy suggests CABG (n  294) (n  283)
Acute, n (%) 261 (88.8) 268 (94.7) 0.007
Pre-operative statin use, n (%) 217 (72.8) 203 (68.1) 0.209
ASA scores, n (%) (n  296) (n  296)
2–3 47 (15.9) 40 (13.5) 0.416
4–5 249 (84.1) 256 (86.5) 0.416
Repeat CABG, n (%) 17 (5.7) 13 (4.4) 0.454
Emergent cases, n (%) 36 (12.1) 21 (7.0) 0.037
Urgent cases, n (%) 205 (68.8) 194 (65.1) 0.338
Elective cases, n (%) 57 (19.1) 83 (27.9) 0.012
Number of vessel grafts (SD) 3.38 (1.13) 3.73 (1.20) 0.001
Graft site, n (%) (n  298) (n  298)
Distal vein 244 (81.8) 249 (83.6) 0.588
LIMA 251 (84.2) 275 (92.3) 0.002
RIMA 6 (2) 3 (0.1) 0.313
Both LIMA and RIMA 5 (1.6) 4 (1.3) 0.737
Right radial artery 1 (1) 2 (11) 0.563
Left radial artery 20 (6.7) 25 (8.4) 0.438
Both radial arteries 0 1 (1) 0.317
Not available 3 (1.0) 1 (1) 0.317
Postponed surgery (n  46) (n  32)
Due to antiplatelet therapy, n (%) 35 (76.1) 10 (31.3) 0.001
Due to recent MI, n (%) 4 (8.7) 10 (31.3) 0.011
Due to recent CVA, n (%) 2 (4.3) 0 0.510
Sent home, n (%) 3 (6.5) 4 (12.5) 0.436
Remained in hospital, n (%) 43 (93.5) 28 (87.5) 0.436
Postponed with sudden change to emergent status, n (%) 3 (6.5) 0 0.265
Days surgery postponed, median (range) 5 (2–7) 6 (1–9) 0.050
Other surgical data
On-pump, n (%) 215 (72.1) 216 (72.5) 0.927
Duration of pump (min), mean (SD) 95.6 (41.20) 94.2 (36.12) 0.929
Duration of surgery (min), mean (SD) 225.5 (73.30) 226.9 (64.1) 0.538
Time from admission to CABG (days), mean (SD) 2.5 (2.57) 2.8 (2.48) 0.950
Time from PCI to CABG (h), mean (SD) 43.7 (44.19) 47.2 (49.26) 0.809
Perioperative medications, n (%)
Antifibrinolytic drugs 197 (66.1) 166 (55.7) 0.009
Trasylol (aprotinin) 103 (34.6) 95 (31.9) 0.487
Amicar (aminocaproic acid) 93 (31.2) 69 (23.2) 0.027
Cyklokapron (tranexamic acid) 2 (0.7) 5 (1.7) 0.450
Factor VIIa (NovoSeven) 45 (15.1) 34 (11.4) 0.184
Glycoprotein IIIa/IIb inhibitor 48 (16.1) 33 (11.1) 0.073
Aspirin 280 (94.0) 268 (89.9) 0.071
Heparin
UFH 283 (95.0) 280 (94.0) 0.591
LMWH 44 (14.8) 56 (18.8) 0.188
Both UFH and LMWH 11 (3.7) 11 (3.7) 1.000
Statins 217 (72.8) 203 (68.1) 0.209
Beta-blockers 245 (82.2) 217 (72.8) 0.006Continued on next page
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CABG in ACS With Clopidogrel November 18, 2008:1693–701r clinical outcomes reflecting 1 hospital with or without
xpertise in the management of patients with ACS. Finally,
he patients reflect those encountered regularly in clinical
ractice, rather than an inherently lower-risk group of
atients participating in clinical trials (16).
Continued
Table 2 Continued
Calcium-channel blockers
Thrombolytic agents
*Binary variables compared by chi-square or Fisher exact tests and c
skewed data. †Some patients were diagnosed with both unstable ang
ACS  acute coronary syndrome; ASA  American Society of Anes
weight heparin; NSTE  non–ST-segment elevation; RIMA  right int
heparin; other abbreviations as in Table 1.
rimary and Secondary Outcomes, Unadjusted
Table 3 Primary and Secondary Outcomes, Unadjusted
Group A
(n  298)
Group B
(n  298)
p
Value*
Primary outcomes
Patients requiring reoperation, n (%) 19 (6.4) 5 (1.7) 0.004
Patients with excessive or major
bleeding,† n (%)
71 (34.5) 53 (25.6) 0.049
In-patient LOS, days (SD) 9.7  6.0 8.6  4.7 0.016
Secondary outcomes
Reoperation for bleeding
complication, n (%)
14 (4.7) 4 (1.3) 0.017
CURE major bleeding, n (%) 113 (53.8) 73 (34.9) 0.001
TIMI major bleeding, n (%) 114 (54.3) 98 (46.9) 0.130
Nonlife-threatening bleeding,‡
n (%)
56 (18.8) 55 (18.5) 0.916
In-hospital death, n (%) 4 (1.3) 1 (0.3) 0.373
Death/reinfarction/stroke, n (%) 8 (2.7) 5 (1.7) 0.400
Transfusion received, mean units§
(SD)
4.90 (7.90) 2.03 (3.75) 0.001
Hospital readmission within 30 days 27 (9.1) 24 (8.1) 0.670
Post-surgical LOS, days (SD) 7.2 (5.53) 6.3 (3.87) 0.054
ICU LOS, days (SD) 2.7 (3.17) 2.4 (2.52) 0.059
Post-operative complications, n (%)
Atrial fibrillation 70 (23.5) 56 (18.8) 0.160
Infection 22 (7.4) 17 (5.7) 0.408
Ischemic CVA 5 (1.7) 3 (1.0) 0.725
Hemorrhagic CVA 0 0 —
Post-operative mortality 3 (1.0) 0 0.249
Hemodynamic instability 37 (12.4) 25 (8.4) 0.107
Inotropes needed 102 (34.2) 73 (24.5) 0.009
Mediastinitis 2 (0.7) 0 (0.0) 0.157
Bleeding/tamponade 20 (6.7) 7 (2.3) 0.010
Cardiac arrest 4 (1.3) 2 (0.7) 0.686
Binary variables compared by chi-square or Fisher exact tests and continuous variables compared
y Student t test or Mann-Whitney U test for skewed data. †Some cases were missing the
ecessary Hg values for this definition, thus, n  206 and n  207, respectively, comprise the
roup analyzed for this parameter. Major bleeding includes patients with fatality due to bleeding,
post-operative decrease in hemoglobin concentration of 5 g/dl, hypotension requiring the use
f inotropes post-operatively or surgical intervention, or intracranial bleeding. ‡Nonlife-threatening
leeding was defined as bleeding that required transfusion of 2 but 4 units of blood products
n the intraoperative and post-operative period combined. §Includes intraoperative and post-
perative transfusions of all types of blood products (platelets, packed red blood cells, fresh frozen
lasma, cryoprecipitate), all patients included; if no blood products were transfused, the individual
atient’s total was 0.
CURE  Clopidogrel in Unstable Angina to Prevent Recurrent Events study; CVA  cerebrovas-ular accident; ICU intensive care unit; LOS length of stay; TIMI Thrombolysis In Myocardial
nfarction study. OThe highly significant relationship between clopidogrel
xposure and reoperation or major bleeding after CABG
as independent of other factors known to play an impor-
ant role in hemostasis. Among patients in Group A, the
dds of requiring reoperation were increased nearly 5-fold.
n addition, patients were at risk for major bleeding, and
ad an increased LOS. Importantly, risk decreased with
ach subsequent day between clopidogrel exposure and
ABG, reaching the background level of risk at 6 days
etween the cessation of clopidogrel and surgery. To our
nowledge, this important relationship has not been clari-
ed previously.
Clopidogrel is an irreversible platelet P2Y12 receptor
ntagonist (17). From the time of drug discontinuation,
estoration of normal hemostasis is dependent upon the
ntroduction of platelets into the circulation from bone
arrow and extramedullary sources. Studies on the anti-
latelet effect of clopidogrel have shown a time-dependent
roup A (n  298) Group B (n  298) p Value*
56 (18.8) 48 (16.1) 0.388
10 (3.4) 2 (0.7) 0.020
us variables compared by Student t test or Mann-Whitney U test for
NSTE ACS.
gists; LIMA  left internal mammary artery; LMWH  low molecular
ammary artery; STE  ST-segment elevation; UFH  unfractionated
ogistic Regressionodel of Predict ng Reoperation
Table 4 Logistic RegressionModel of Predicting Reoperation
Variable OR
95% Confidence
Interval
p ValueLower Upper
Clopidogrel exposure 5 days 4.601 1.454 14.554 0.009
Age 0.998 0.952 1.046 0.941
Female gender 2.091 0.766 5.708 0.150
Body mass index 1.042 0.970 1.119 0.258
History of alcohol abuse 4.383 0.946 20.315 0.059
History of renal insufficiency 2.179 0.555 8.554 0.264
Admission creatinine clearance
60 ml/min
0.807 0.278 2.341 0.693
Perioperative exposure to
antifibrinolytic agents
2.314 0.629 8.512 0.207
Pre-operative exposure to
thrombolytic agents
0.942 0.071 12.479 0.964
Pre-operative exposure to
glycoprotein IIb/IIIa inhibitors
1.825 0.504 6.613 0.360
Pre-operative exposure to
aspirin
0.616 0.109 3.483 0.584
History of both MI and PCI 0.675 0.027 16.772 0.811
Pre-operative ejection fraction 1.004 0.968 1.042 0.817
History of previous CABG 5.299 1.050 26.734 0.043
ASA score 4–5 0.312 0.101 0.964 0.043
Urgent surgical classification 1.645 0.420 6.451 0.475
Emergent surgical classification 1.155 0.134 9.963 0.896
On-pump CABG 0.353 0.099 1.264 0.110G
ontinuo
ina and
thesioloR  odds ratio; other abbreviations as in Tables 1 and 2.
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November 18, 2008:1693–701 CABG in ACS With Clopidogrelesponse with complete recovery of platelet function 7 days
fter the last dose (18). Because cardiothoracic surgery
epresents a major hemostatic challenge (19) and is required
n upward of 15% of patients admitted to the hospital with
CS (7–9), clinicians are confronted regularly with complex
ecisions concerning clopidogrel cessation and surgical re-
ascularization. In fact, data from the CRUSADE (Can
apid Risk Stratification of Unstable Angina Patients
uppress Adverse Outcomes With Early Implementation of
he ACC/AHA Guidelines) initiative noted that 30% of
atients undergoing CABG received clopidogrel on admis-
ion for ACS, and 87% of these patients went to surgery5
ays from their last clopidogrel dose (9). Although the
CC/AHA guidelines recommend waiting 5 to 7 days
etween clopidogrel exposure and CABG, the committee
embers ask for more data to help dictate patient care (5).
o add further complexity to the decision-making process,
he recently published TRITON–TIMI 38 (Trial to Assess
mprovement in Therapeutic Outcomes by Optimizing
latelet Inhibition With Prasugrel–Thrombosis In Myocar-
ial Infarction 38) study (20), showed that prasugrel re-
uced myocardial infarction compared with clopidogrel, but
t a cost of increased major and life-threatening hemor-
hage. Among patients undergoing CABG, there was a 10%
bsolute increase in major bleeding among those receiving at
east 1 dose of prasugrel (20). Thus, as for clopidogrel and
ther platelet antagonists, the role and timing of prasugrel
se in the setting of cardiac surgery will need to be
nvestigated thoroughly.
Several studies have evaluated the relationship between
lopidogrel exposure and cardiovascular morbidity after
ABG. Many of these studies included differing patient
opulations; 2 studies included patients with non–ST-
levation ACS (9,13), 2 included urgent or emergent
Figure 2 Incidence of Composite Outcome by Day Clopidogrel S
The composite outcome (reoperation or major bleeding) incidence is shown by day
is the total number of patients who were exposed to clopidogrel 7 days (n  32ABG (11,12), and 2 included low-risk CABG (10,14).
*
plthough not all did (10), most identified a significant
ssociation between clopidogrel exposure and major hem-
rrhage (9,11–14). Nevertheless, only 2 studies reported
djusted rates of major bleeding, with ORs that ranged from
.4 to 4.2 (9,12). However, no previously published study
valuated the adjusted risk for reoperation. Our study was
esigned to assess whether exposure to clopidogrel had a
ignificant effect on the risk of major bleeding and reopera-
ion. In the CURE trial (3), patients undergoing CABG
ho were exposed to clopidogrel within 5 days before
urgery experienced a 3.3% absolute increase of major
emorrhagic complications. Moreover, they demonstrated
n increased risk for reoperation (relative risk: 1.79, 95% CI:
.85 to 3.74) (3). The wide confidence interval precluded a
rm conclusion from being drawn. An important distin-
uishing feature between the CURE study and the present
tudy is the time interval between ACS and surgical
evascularization. In the CURE study, the mean time
elationship Between Clopidogrel andransfusion and Ch st Tube Output, Unadjusted
Table 5 Relationship Between Clopidogrel andTransfusion and Chest Tube Output, Unadjusted
Group A
(n  298)
Group B
(n  298) p Value*
Transfusions, n (%)
Pre-operative 5 (1.7) 4 (1.3) 0.751
Intraoperative 128 (43.0) 96 (32.2) 0.007
Post-operative 149 (50.0) 106 (35.6) 0.001
Chest tube output, ml (SD)
0–3 h 219.6 (177.07) 174.01 (120.3) 0.005
3–6 h 139.9 (137.77) 114.6 (94.9) 0.083
6–12 h 181.2 (260.68) 151.5 (141.94) 0.979
12–18 h 127.5 (108.70) 117.0 (96.68) 0.375
Total 668.3 (515.50) 557.2 (339.01) 0.026
ed Before Surgery
ogrel was stopped before surgery. The denominator for the points on this curve
patients experienced the composite outcome. Red line  clopidogrel exposure.topp
clopid
9); 89Binary variables compared by chi-square or Fisher exact tests, and continuous variables com-
ared by Student t test or Mann-Whitney U test for skewed data.
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CABG in ACS With Clopidogrel November 18, 2008:1693–701etween ACS and CABG was 25.5 days, whereas in the
resent analysis, CABG was performed within 7 days of
ospitalization or angiography for ACS.
We also assessed the impact of other clinical features on
he risk of major bleeding or reoperation. Similar to previ-
us models for bleeding (21,22), we found a significant
elationship between older age and female gender on the
isk of reoperation and major bleeding. We also found
vidence of increased morbidity among patients with a
istory of alcohol abuse. This finding is consistent with the
xcess risk of hemorrhagic stroke among patients who are
oderate or heavy drinkers (23–26).
tudy limitations. Retrospective studies must address con-
erns about bias (27). We minimized potential bias by
ccruing the study population from multiple sites, by rep-
esenting each geographic region in the U.S., and by
andomly selecting patients in each cohort and at each site
ccording to prospectively designed inclusion and exclusion
riteria to reduce confounders of variability in surgical
ractice, standards of care, or hospital setting. It is also
nlikely that a greater proportion of Group A patients were
nherently at greater risk for reoperation given the absence
f differences between groups for known risk factors and
erioperative characteristics. Although patients in Group A
ad a greater prevalence of prior myocardial infarction and
ercutaneous coronary intervention than did patients in
roup B, it is unlikely that this small difference accounted
or the 5-fold relative odds of reoperation. Our results are
ot based on patient self-report of clopidogrel cessation
efore CABG. All patients underwent surgery during their
ndex hospitalization for ACS, providing carefully collected
nformation for abstraction from medical records at each
articipating institution.
The association we observed between clopidogrel admin-
stration and reoperation has several important features of a
ausal relationship (27). It is strong, time dependent, and
iologically plausible. It follows an appropriate temporal
equence, and is supported by previous reports. In addition,
he relationship persisted after controlling for a variety of
otential confounders.
onclusions
fter ACS, patients who undergo CABG within 5 days of
eceiving clopidogrel are at increased risk for reoperation,
ajor bleeding, and a prolonged LOS. In multivariate
nalysis, clopidogrel exposure within 5 days was the stron-
est predictor of reoperation. For the first time, we clearly
emonstrate a relationship between the proximity of clopi-
ogrel exposure to the time of surgery and the risk of
eoperation or major bleeding. Nevertheless, these risks
ust be balanced by the benefits of clopidogrel use demon-
trated in randomized clinical trials. Future studies are
equired to investigate safe and effective strategies to reduce
lopidogrel-related perioperative hemorrhagic bleeding
omplications.
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APPENDIX
or a list of hospitals, health care centers, and coinvestigators
nvolved in this study, please see the online version of this article.
